| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.089 | 0.9 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |